Cyamemazine

In response to clinical challenges such as anxiety and agitation associated with positive symptoms of schizophrenia, phenothiazine derivatives with both antipsychotic and sedative effects have gradually become a key focus in the segmented field. Cyamemazine, a typical thienophenothiazine antipsychotic drug, exerts multiple pharmacological effects by blocking central dopamine D2 receptors, 5-hydroxytryptamine receptors and α-adrenergic receptors. It is not only suitable for the control of acute agitation in schizophrenia, but also can be used to relieve anxiety and restlessness associated with organic mental disorders and manic episodes. Some countries have also included it in the adjuvant treatment regimen for severe refractory pruritus, covering the medication needs of multiple departments such as adult psychiatry and dermatology.

The continuous rise in the global prevalence of mental disorders has driven the expansion of the segmented antipsychotic drug market. Currently, the global market size of second-generation phenothiazine drugs with low sedative side effects, including cyamemazine, is approximately USD 120 million, with a compound annual growth rate of around 3.7%. Due to the early launch time of this drug, the European market is mainly supplied by the original research manufacturer and local generic enterprises, while there is no large-scale generic layout in China, and the market is in an undeveloped state. Publicly verifiable domestic epidemiological and medication data are temporarily unavailable.

The original research manufacturer of cyamemazine is Sanofi, with the original brand name Lergetm. The core compound patent of this drug expired globally in 1999. The main dosage forms approved for the original product are tablets and injections. The tablet specifications include 25mg and 50mg, and the injection specification is 50mg/2ml. It has been included in the reference preparation catalogs of EU countries such as France and Germany, and has not yet been included in the *List of Chemical Drugs* of China. There are no cyamemazine preparation products approved for marketing in China for the time being, and no valid API registration number in A status has been found on the CDE API registration platform. (Data as of August 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for cyamemazine API, fully covering the research needs of process impurities and degradation impurities. Most products can be supplied from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All reference standards comply with the regulatory requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable support for impurity control in drug R&D, quality research and production links.